Developing a vaccine to protect against West Nile virus infection
Official title: Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant
Funded at Hawaii Biotech, INC. · NIH-10678482 · Data updated 2026-11-12
This study is working on a new way to make vaccines for the West Nile virus even better, which could help protect people from serious health issues caused by the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hawaii Biotech, INC. NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project start | July 5, 2022 |
| Project end | July 5, 2025 |
| Funding year | 2022 |
| Award (this year) | $2,997,218 |
| NIH project number | 75N93022C00034-0-9999-1 |
| Project ID | NIH-10678482 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of West Nile virus exposure, particularly those living in endemic areas.
✕Less likely to help
Patients who are not at risk of West Nile virus infection or those who have already been vaccinated may not receive any benefit from this research.
What this research studies
This research focuses on creating a vaccine adjuvant that enhances the immune response to the West Nile virus. It utilizes a TLR4 agonist combined with an oil-in-water emulsion to improve vaccine effectiveness. Patients may benefit from this research as it aims to provide better protection against West Nile virus infections, which can lead to serious health complications. The approach involves rigorous testing and formulation optimization to ensure safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the risk of West Nile virus infection.
How similar studies have gone: Other research has shown promise in using TLR4 agonists as vaccine adjuvants, indicating potential for success in this approach.
Where this research is happening
-
Hawaii Biotech, INC.
Honolulu, United States Active
Researchers
- Principal investigator: Clements, David — Hawaii Biotech, INC.
- Study coordinator: Clements, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.